Van Eeden Susanne, Quaedvlieg Pascal F H J, Taal Babs G, Offerhaus G Johan A, Lamers Cornelis B H W, Van Velthuysen Marie-Louise F
Department of Pathology, Academic Medical Centre, University of Amsterdam, Amsterdam Departments of Medical Oncology and Pathology of the Netherlands Cancer Institute, The Netherlands.
Hum Pathol. 2002 Nov;33(11):1126-32. doi: 10.1053/hupa.2002.129204.
Metastasized neuroendocrine tumors of the gastrointestinal tract and of unknown origin show a highly variable clinical course. Within this group, low-grade and high-grade malignant tumors can be recognized based on the revised classification of neuroendocrine tumors of the lung, pancreas, and gut published by Capella et al in 1995. The present study investigated whether fine-tuning the prediction of prognosis was possible by dividing the group of low-grade malignant tumors of the midgut and of unknown origin into typical and atypical carcinoids by grading them according to the World Health Organization (WHO) classification criteria for neuroendocrine tumors of the lung. Moreover, the prognostic value of immunohistochemical stainings and clinical parameters was evaluated. The study group comprised patients diagnosed between 1983 and 1999 with liver metastases of a neuroendocrine tumor of the midgut n = 40) or of unknown origin (n = 16). As a control for the consistency of grading, 10 patients with metastasized neuroendocrine tumors of the lung also were evaluated. Immunohistochemical stainings for chromogranin A, synaptophysin, Leu 7/CD57, neural cell adhesion molecule/CD56, cytokeratin 8, bcl-2, p53, ki67, and HER2/neu were performed. The clinical parameters age, gender, urinary 5-HIAA level, and presence or absence of the carcinoid syndrome were evaluated. Tumors of the midgut and of unknown origin were evaluated together, because they were clinically similar. In this group of 56 patients, both the Capella and the WHO classification systems recognized the high-grade malignant tumors with a bad prognosis. When the low-grade malignant tumors (Capella) were divided into typical and atypical carcinoids (WHO), no difference in survival was observed, but when the dichotomy into typical and atypical was based on mitotic count alone, the difference became borderline significant (P =.072). Of the immunohistochemical stainings used, synaptophysin, cytokeratin 8, and ki67 had limited prognostic value. Age above 60 was the only clinical parameter of unfavorable prognostic significance. We conclude that high-grade malignant neuroendocrine tumors of the midgut and of unknown origin are recognized by both the Capella classification and the WHO classification of neuroendocrine tumors of the lung. Further subdividing low-grade malignant tumors at this location appears to be of less value than in the lung, but assessing the mitotic activity of these tumors might be of prognostic value.
胃肠道及不明原发部位的转移性神经内分泌肿瘤临床病程高度多变。在这一肿瘤群体中,根据卡佩拉等人于1995年发布的肺、胰腺及肠道神经内分泌肿瘤修订分类,可识别出低级别和高级别恶性肿瘤。本研究探讨了依据世界卫生组织(WHO)肺神经内分泌肿瘤分类标准,将中肠及不明原发部位的低级别恶性肿瘤分为典型类癌和非典型类癌,是否有可能对预后预测进行微调。此外,还评估了免疫组化染色及临床参数的预后价值。研究组包括1983年至1999年间被诊断为中肠神经内分泌肿瘤肝转移(n = 40)或不明原发部位神经内分泌肿瘤肝转移(n = 16)的患者。作为分级一致性的对照,还评估了10例肺转移性神经内分泌肿瘤患者。进行了嗜铬粒蛋白A、突触素、Leu 7/CD57、神经细胞黏附分子/CD56、细胞角蛋白8、bcl-2、p53、ki67及HER2/neu的免疫组化染色。评估了年龄、性别、尿5-羟吲哚乙酸水平及类癌综合征是否存在等临床参数。中肠及不明原发部位的肿瘤一起评估,因为它们在临床上相似。在这56例患者中,卡佩拉分类系统和WHO分类系统均识别出预后不良的高级别恶性肿瘤。当将低级别恶性肿瘤(卡佩拉分类)分为典型类癌和非典型类癌(WHO分类)时,未观察到生存差异,但仅基于有丝分裂计数进行典型与非典型的二分法时,差异接近显著(P = 0.072)。在所使用的免疫组化染色中,突触素、细胞角蛋白8及ki67的预后价值有限。60岁以上是唯一具有不良预后意义的临床参数。我们得出结论,卡佩拉分类及WHO肺神经内分泌肿瘤分类均能识别中肠及不明原发部位的高级别恶性神经内分泌肿瘤。在此部位进一步细分低级别恶性肿瘤似乎比在肺中价值更小,但评估这些肿瘤的有丝分裂活性可能具有预后价值。